Mass spectrometry has numerous applications in pharmaceutical research, from initial discovery through to characterisation and quality control. In this article, Dr Ioannis Papayannopoulos details the role of mass spectrometry in pharma R&D by highlighting established and novel applications of the technique in drug discovery and development.
List view / Grid view
Filter the results
GEA’s digitally-enabled process optimisation tools improve the customer experience and expedite the successful completion of pharmaceutical research, development and production projects. This comprehensive suite of process simulations, digital twins, augmented/virtual reality systems and remote support solutions represents a safe and effective environment in which to achieve operational excellence, expedite FATs,…
PerkinElmer will expand its automated life sciences discovery and applied genomics solutions with the acquisition.
In this article Pramod Kumar, a Senior Research Analyst (Healthcare) at P&S Intelligence, explores how single-cell analysis techniques are used for both pharmaceutical R&D and clinical, diagnostic applications.
The fund has already raised $1 billion to support clinical research of novel antibiotics and intends to bring up to four new antibiotics to market by 2030.
The NHS is offering two contracts to pay pharma companies at the start of their research into antibiotics, to promote the development of new antimicrobials.
The US FDA approved Phexxi™ (lactic acid, citric acid and potassium bitartrate) gel, the first non-hormonal, vaginal pH regulator contraceptive.
A group of four CROs at BioCity Nottingham have joined forces to collectively work on the research of COVID-19 therapies.
Heidi West discusses how academia, government and the pharmaceutical industry can work together to potentially repurpose drugs for the treatment of COVID-19.
The UK MRC and LifeArc are making £16 million available as grants to fund the establishment of Gene Therapy Innovation Hubs to improve resources for researchers and manufacturers.
A polio vaccine designed to be incapable of evolving the ability to cause disease in humans has shown promise in a Phase I clinical trial.
While medical professionals fight COVID-19 on the front line, small biotech businesses face a new uphill battle – maintaining research continuity for non-COVID-19 life-changing therapeutics.
The coalition has been formed to find R&D solutions for low- and middle-income countries to limit the impact of the COVID-19 pandemic in areas with fragile healthcare systems.
The European Medicines Agency (EMA) announced it will provide free advice to those working on COVID-19 therapeutics and vaccines in the hopes of accelerating approval of a treatment.
New research suggests the flow cytometry sector will grow at a CAGR of 8.2 percent due to increased adoption and expanding uses.